# Vesper Ventures SA

> Vesper Ventures SA is a VC fund backing Biotechnology and Genetics. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Florianópolis, Brazil
- Total investments: 10
- Last investment: Jan 2025
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/vesperventurebuilder
- Website: https://www.vesper-ventures.com/

Vesper Ventures SA is a VC fund in Florianópolis focused on Biotechnology and Genetics. Vesper is a venture building company with focus on biotech's. ​Our mission is to help passionate and talented scientists, entrepreneurs and visionaries transform innovative ideas into great companies.

## Contacts

5 contacts available for Vesper Ventures SA. Shizune tracks 2 team members at Vesper Ventures SA. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/vesper-ventures-sa?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $200k–$4.5M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 80% |
| Genetics | 3 | 30% |
| Agriculture | 2 | 20% |
| Organic | 1 | 10% |
| Life Science | 1 | 10% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 5 | 50% |
| Seed | 3 | 30% |
| Venture - Series Unknown | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Brazil | 6 | 60% |
| United States | 2 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gabriel Mantovani Bottós | Co-Founder, CEO, and Senior Partner | 0 | https://shizune.co/investors/profile/gabriel-mantovani-bott%C3%B3s |
| Rafael Mantovani Bottós | Co-Founder | 0 | https://shizune.co/investors/profile/rafael-mantovani-bott%C3%B3s |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vyro Bio | Vyro is an immuno-oncology (I-O) biotechnology company developing cancer-killing, or ‘oncolytic’, viruses (OVs) designed to target adult and pediatric central nervous system (CNS) tumors, based on pioneering research and breakthrough discovery of the oncolytic properties of the Zika Virus (ZIKV). | $200K | Seed | Jan 01, 2025 |  |
| Symbiomics | Symbiomics provides the next-generation biologicals based on robust-colonizing microbes for plant growth improvement through sequencing technologies, machine learning, and genome editing tools. |  | Venture - Series Unknown | Dec 14, 2023 |  |
| HapiSeeds | HapiSeeds develops new technologies aimed at Sustainable Agriculture, increasing food production through environmentally friendly practices. These technologies involve the development of new commercial plant varieties, either through plant engineering with genome editing or by assisting plant breeders and farmers with molecular tools to achieve:increased biomass and plant productivity; reduced use of chemical fertilizers through innovative cultivation technologies (bioinoculants); lower irrigation requirements; higher yield per cultivated area; and reduced pesticide use by enhancing disease resistance. |  | Pre-Seed | Dec 01, 2023 |  |
| Cellertz Bio | Cellertz Bio is a biotech company. Their integrated in silico and experimental approach is designed to generate the next generation of cell therapies against cancer and other diseases by precisely controlling gene regulatory networks defining cell behaviors. Their goal is to determine which genes to control to achieve their cell therapy goals |  | Pre-Seed | Mar 01, 2023 |  |
| Symbiomics | Symbiomics provides the next-generation biologicals based on robust-colonizing microbes for plant growth improvement through sequencing technologies, machine learning, and genome editing tools. |  | Pre-Seed | Mar 07, 2022 |  |
| InEdita Bio | InEdita’s nature-inspired, non-transgenic, genome-edited crop varieties reduce the use of chemical pesticides in food productionBy changing the genetic code encrypted in a text with millions of messages resulting from the combination of four letters (A, C, G, and T), InEdita Bio creates plants resistant to pests and diseases and enhanced waterand nutrient use efficiency. |  | Pre-Seed | Mar 01, 2022 |  |
| Vyro Bio | Vyro is an immuno-oncology (I-O) biotechnology company developing cancer-killing, or ‘oncolytic’, viruses (OVs) designed to target adult and pediatric central nervous system (CNS) tumors, based on pioneering research and breakthrough discovery of the oncolytic properties of the Zika Virus (ZIKV). | $1.5M | Seed | Feb 19, 2022 |  |
| FUTR BIO | FUTR BIO is a biotechnology company that aims to prevent and cure diseases such as infections and cancer. They focused on developing mRNA vaccines. They developed mRNA vaccine technologies to induce immune responses by fine-tuning control of the mammalian immune system. |  | Pre-Seed | Feb 12, 2022 |  |
| Reddot.bio | Reddot.bio is a biotech company that provides an unique and powerful diagnostic platform to accurately identify genetic traces |  | Seed | Jan 01, 2022 |  |
| Aptah Bio | Imagine a world where age-related diseases are things of the past! That’s the potential Aptah Bio is unlocking. We are working with leading global scientists, laboratories, and the best patent attorneys to develop the next pharmaceutical blockbuster with a multi-billion dollar market value, able to impact the lives of millions of people.AptahBio’s compound significantly reduces age-related random RNA processing errors, thus eliminating multiple faulty RNAs and resulting toxic proteins with one compound. Its utility spans across multiple therapeutic categories, including age-related neurodegenerative diseases and cancer, areas of high unmet medical need, and significant commercial potential. As the global population ages, age-related diseases have become a significant, growing concern and socioeconomic burden, currently inadequately addressed by existing therapies.Our therapy holds the potential to address the root cause of many of these age-related dysfunctional proteins and the diseases they cause. | $4.5M | Seed | Jan 20, 2021 |  |

10 of 10 investments shown.

## Co-investors
- [Baraúna Venture Capital](https://shizune.co/investors/profile/bara%C3%BAna-vc) — VC Fund, 1 deal together
- [Ecoa Capital](https://shizune.co/investors/profile/ecoa-capital) — VC Fund, 1 deal together
- [MOV Investimentos](https://shizune.co/investors/profile/mov-investimentos) — VC Fund, 1 deal together
- [The Yield Lab LATAM](https://shizune.co/investors/profile/the-yield-lab-latin-america) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

### Similar country
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [DOMO.VC](https://shizune.co/investors/profile/domo-invest) — VC Fund
- [Canary](https://shizune.co/investors/profile/canary-5) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in LATAM](https://shizune.co/investors/biotechnology-investors-latam)
- [Biotechnology VC Funds in LATAM](https://shizune.co/investors/biotechnology-vc-funds-latam)
- [Biotechnology Investors in Brazil](https://shizune.co/investors/biotechnology-investors-brazil)
- [Biotechnology VC Funds in Brazil](https://shizune.co/investors/biotechnology-vc-funds-brazil)
- [Biotech VC Funds in LATAM](https://shizune.co/investors/biotech-vc-funds-latam)
- [Biotech Investors in Brazil](https://shizune.co/investors/biotech-investors-brazil)

## FAQ

### What does Vesper Ventures SA invest in?

Vesper Ventures SA invests primarily in Biotechnology, Genetics and Agriculture startups, most often at Pre-Seed and Seed stage. Most of the 10 investments tracked by Shizune back companies in Brazil. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Vesper Ventures SA's check size?

Vesper Ventures SA typically joins rounds of $200k–$4.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Vesper Ventures SA participates in.

### How do I contact Vesper Ventures SA?

Public channels for Vesper Ventures SA include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Vesper Ventures SA?

The team at Vesper Ventures SA includes Gabriel Mantovani Bottós (Co-Founder, CEO, and Senior Partner) and Rafael Mantovani Bottós (Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co